Merck Serono and Newron initiate second Phase III trial in advanced Parkinson's
This article was originally published in Scrip
Executive Summary
Merck Serono and Newron have begun a second Phase III Parkinson's trial of their investigational adjunctive therapy to levodopa, safinamide.